Introdução: Portadores de fibrose cística têm uma susceptibilidade à deficiência de vitamina D devido à má absorção de nutrientes. Os estudos da prevalência de hipovitaminose D em pacientes com fibrose cística apresentam resultados extremamente variáveis e não há dados a respeito da população não pediátrica no Brasil. Objetivos: Avaliar a prevalência de hipovitaminose D em pacientes não pediátricos portadores de fibrose cística e os fatores associados com as concentrações séricas de 25-hidroxivitamina D. Metodologia: Realizado estudo transversal. A população em estudo foi composta por pacientes maiores que 16 anos acompanhados no Ambulatório de Fibrose Cística do Hospital de Clínicas de Porto Alegre. Foi avaliada a prevalência de deficiência de vitamina D, definida como 25-hidroxivitamina D < 30ng/mL, de acordo com a Cystic Fibrosis Foundation, bem como os fatores clínicos e laboratoriais associados com o valor sérico desta. Foram avaliados o estado nutricional e internações hospitalares. Foi realizada coleta de dados em prontuário, entrevista com os pacientes e colheita de sangue. As análises laboratoriais foram realizadas no Laboratório de Patologia Clínica do Hospital. Foram dosados os valores séricos de proteína C-reativa, cálcio, fosfato, magnésio, albumina, 25-hidroxivitamina D (método: quimiluminescência) e paratormônio (método: imunoensaio para PTH intacto). A função pulmonar foi avaliada por espirometria e escores clínicos e radiológicos. O nível de significância estatística foi estabelecido como P<0,05. Resultados: A prevalência de hipovitaminose D foi de 61,0%, com valores séricos de 25-hidroxivitamina D de 28,42±10,94 ng/mL. Os pacientes com insuficiência pancreática apresentaram uma tendência a ter concentrações mais altas de vitamina D. Dezesseis pacientes apresentavam doença pulmonar grave, com FEV1% do predito inferior a 40%. Após análise multivariada, índice de massa corporal e hospitalizações no último mês permaneceram significativamente associados negativamente aos valores séricos de 25-hidroxivitamina D. Conclusões: A prevalência de hipovitaminose D no presente estudo foi inferior a previamente relatada. A insuficiência de vitamina D continua sendo um problema nos pacientes com fibrose cística, mesmo naqueles recebendo suplementação. / Introduction: Cystic fibrosis patients have a susceptibility to vitamin D deficiency due to nutrient malabsorption. Prevalence studies of hypovitaminosis D in patients with cystic fibrosis have highly variable results and there is no data about the non pediatric population in Brazil. Objectives: To evaluate the prevalence of hypovitaminosis D in non pediactric cystic fibrosis patients and the factors associated with serum 25-hydroxyvitamin D levels. Methods: Cross-sectional study. The study population was composed of patients older than 16 years accompanied in the Cystic Fibrosis Ambulatory of the Hospital de Clínicas de Porto Alegre. We evaluated the prevalence of vitamin D deficiency defined as 25-hydroxyvitamin D < 30 ng/mL, as suggested recently by the Cystic Fibrosis Foundation, and clinical and laboratory factors associated with its serum levels. Nutritional status and hospital admissions were evaluated. Data was collected from medical records and interviews with patient, blood was collected. Laboratory analisys were performed at Clinical Pathology Laboratory of the Hospital. Serum C-reactive protein, calcium, phosphate, magnesium, albumin, 25-hydroxyvitamin D (method: chemiluminescence), and parathyroid hormone levels (method: sandwich immunoassay to intact PTH) were measured. Lung function was evaluated by spirometry and clinical and chest radiographic scores were assessed. Statistical significance level was set at P<0.05. Results: Prevalence of hypovitaminosis D was 61.0 %, with serum 25-hydroxyvitamin D levels of 28,42±10,94 ng/mL. Patients with pancreatic insufficiency had a trend to have higher vitamin D levels. Sixteen patients had severe lung disease with FEV1% predicted below 40%. After multivariable analysis, body mass index and hospitalization in the last month remained significantly associated negatively with serum 25-hydroxivitamin D levels. Conclusions: The prevalence of hypovitaminosis D in the present study was inferior to previously related. Vitamin D insufficiency is still a problem in cystic fibrosis patients, even in those receiving supplementation.

Introdução: Portadores de fibrose cística têm uma susceptibilidade à deficiência de vitamina D devido à má absorção de nutrientes. Os estudos da prevalência de hipovitaminose D em pacientes com fibrose cística apresentam resultados extremamente variáveis e não há dados a respeito da população não pediátrica no Brasil. Objetivos: Avaliar a prevalência de hipovitaminose D em pacientes não pediátricos portadores de fibrose cística e os fatores associados com as concentrações séricas de 25-hidroxivitamina D. Metodologia: Realizado estudo transversal. A população em estudo foi composta por pacientes maiores que 16 anos acompanhados no Ambulatório de Fibrose Cística do Hospital de Clínicas de Porto Alegre. Foi avaliada a prevalência de deficiência de vitamina D, definida como 25-hidroxivitamina D < 30ng/mL, de acordo com a Cystic Fibrosis Foundation, bem como os fatores clínicos e laboratoriais associados com o valor sérico desta. Foram avaliados o estado nutricional e internações hospitalares. Foi realizada coleta de dados em prontuário, entrevista com os pacientes e colheita de sangue. As análises laboratoriais foram realizadas no Laboratório de Patologia Clínica do Hospital. Foram dosados os valores séricos de proteína C-reativa, cálcio, fosfato, magnésio, albumina, 25-hidroxivitamina D (método: quimiluminescência) e paratormônio (método: imunoensaio para PTH intacto). A função pulmonar foi avaliada por espirometria e escores clínicos e radiológicos. O nível de significância estatística foi estabelecido como P<0,05. Resultados: A prevalência de hipovitaminose D foi de 61,0%, com valores séricos de 25-hidroxivitamina D de 28,42±10,94 ng/mL. Os pacientes com insuficiência pancreática apresentaram uma tendência a ter concentrações mais altas de vitamina D. Dezesseis pacientes apresentavam doença pulmonar grave, com FEV1% do predito inferior a 40%. Após análise multivariada, índice de massa corporal e hospitalizações no último mês permaneceram significativamente associados negativamente aos valores séricos de 25-hidroxivitamina D. Conclusões: A prevalência de hipovitaminose D no presente estudo foi inferior a previamente relatada. A insuficiência de vitamina D continua sendo um problema nos pacientes com fibrose cística, mesmo naqueles recebendo suplementação. / Introduction: Cystic fibrosis patients have a susceptibility to vitamin D deficiency due to nutrient malabsorption. Prevalence studies of hypovitaminosis D in patients with cystic fibrosis have highly variable results and there is no data about the non pediatric population in Brazil. Objectives: To evaluate the prevalence of hypovitaminosis D in non pediactric cystic fibrosis patients and the factors associated with serum 25-hydroxyvitamin D levels. Methods: Cross-sectional study. The study population was composed of patients older than 16 years accompanied in the Cystic Fibrosis Ambulatory of the Hospital de Clínicas de Porto Alegre. We evaluated the prevalence of vitamin D deficiency defined as 25-hydroxyvitamin D < 30 ng/mL, as suggested recently by the Cystic Fibrosis Foundation, and clinical and laboratory factors associated with its serum levels. Nutritional status and hospital admissions were evaluated. Data was collected from medical records and interviews with patient, blood was collected. Laboratory analisys were performed at Clinical Pathology Laboratory of the Hospital. Serum C-reactive protein, calcium, phosphate, magnesium, albumin, 25-hydroxyvitamin D (method: chemiluminescence), and parathyroid hormone levels (method: sandwich immunoassay to intact PTH) were measured. Lung function was evaluated by spirometry and clinical and chest radiographic scores were assessed. Statistical significance level was set at P<0.05. Results: Prevalence of hypovitaminosis D was 61.0 %, with serum 25-hydroxyvitamin D levels of 28,42±10,94 ng/mL. Patients with pancreatic insufficiency had a trend to have higher vitamin D levels. Sixteen patients had severe lung disease with FEV1% predicted below 40%. After multivariable analysis, body mass index and hospitalization in the last month remained significantly associated negatively with serum 25-hydroxivitamin D levels. Conclusions: The prevalence of hypovitaminosis D in the present study was inferior to previously related. Vitamin D insufficiency is still a problem in cystic fibrosis patients, even in those receiving supplementation.

Prostate cancer is the most occurring form of cancer in men in Sweden and new candidates for treatment towards advanced phases of prostate cancer needs to be investigated. One suggested treatment is vitamin D which will mediate effect via VDR and PDIA3 and cause cell cycle arrest.  Another treatment is digitoxin which will cause accumulation of intracellular Ca2+ leading to apoptosis. The aim of the project of was to investigate potential synergistic effects of 25-hydroxyvitamin D3 and digitoxin in prostate cancer cell lines and find out effects mediated by PDIA3. DU145 and LNCaP cells were seeded and treated with 25-hydroxyvitamin D3 (10-10, 10-9, 10-7 M), digitoxin (25 ng/ml and 50 ng/ml) and four combinations of 25-hydroxyvitamin D3 and digitoxin. Cell viability assay was performed for determining the number of viable cells. Treatment with 25-hydroxyvitamin D3 10-7M + digitoxin 50ng/ml (68%), 25-hydroxyvitamin D3 10-9M + digitoxin 25ng/ml (39%), 25-hydroxyvitamin D3 10-9M + digitoxin 50ng/ml (69%), digitoxin 25ng/ml (26%) and digitoxin 50 ng/ml (44%) was statistically significant with increased cell viability compared to untreated control in DU145 after 48h of treatment. Treatment with 25-hydroxyvitamin D3 10-7M (12%) and 25-hydroxyvitamin D3 10-9M (12%) was statistically significant with increased cell viability compared to untreated control in LNCaP after 24h of treatment. The conclusion based on results from this study is that a combination of digitoxin and 25-hydroxyvitamin D3 does not inhibit cell viability in DU145 or LNCaP cancer cell lines.

60 % of Canadians have suboptimal vitamin D (<75 nmol/L) and 25% are obese. Obesity has been reported to be a risk factor for low vitamin D, but there is uncertainty about the magnitude of the association. Linear regression was performed using data from the nationally representative cross-sectional Canadian Health Measures Survey (2007-2009). Height, weight, waist circumference (WC), and vitamin D levels were directly measured. There were 5298 participants aged 6 to 79 years. Using a conservative p value of 0.001, body mass index (BMI) category obese / obese I was positively associated and WC was inversely associated with vitamin D level in crude analysis. WC was inversely associated with vitamin D level in multivariate analysis. The pattern of relationship is not the same as other studies, yet this was a large study with direct measurements. There may be issues with linearity of relationships or subgroups disturbing the relationship.

25-Hydroxyvitamin D3[25(OH)D3] is a metabolite of vitamin D3 that has long been considered to be an inactive precursor of the hormonally active metabolite 1,25- dihydroxyvitamin D3[l,25(OH)2D3]; consequently very few studies have addressed the potential biological activity of 25(OH)2D3. However, it is known that 100 nM 25(OH)2D3 increases calcium transport in the perfused duodenal loop of the chicken to 200% of controls within 20 minutes. The hypothesis of the current study is that 25(OH)2D3 may be a hormonally active metabolite and its effects can be studied in isolated chick enterocytes. To begin testing this postulate, time course studies of 45Ca uptake were undertaken in isolated intestinal cells (from 7 wk chicks). After establishing the basal uptake of 45Ca for 5 minutes, cells were treated with vehicle(< 0.01% v/v ethanol, final concentration) or 25 nM, 50 nM, 100 nM, or 300 nM 25(OH)2D3 and samples were taken at T = 1, 3, 5, 7, and 10 min. With increasing concentrations of steroid, the enterocyte 45Ca decreased. The optimal concentration of 100 nM 25(OH)2D3 induced the most rapid response: within 1 min 45Ca decreased to 54% of controls (P < 0.001) and 70% of the controls at T= 3, 5, and 7 min (P < 0.01 to < 0.05, relative to controls). Comparison of the 7- min time points for 25 nM, 50 nM, 100 nM, and 300 nM 25(OH)2D3 appeared to yield a biphasic dose response curve with values of 45Ca observed at 99% (NS, not significant), 75% (P < 0.05), 70%(P < 0.01%), and 80% (NS) of corresponding controls, respectively. Physiological levels of 24,25(OH)2D3 (6.5 nM) inhibited the action of 100 nM 25(OH)2D3 in isolated chick enterocytes. Time course studies with isolated enterocytes from 14 wk and 28 wk chickens treated with 100 nM 25(OH)2D3 also showed decreased responsiveness: at T= 1 min 45Ca levels in 7 wk, 14 wk, and 28 wk were 54% (P < 0.01), 83% (NS), and 80% (NS) of corresponding controls, respectively. Experiments with the calcium channel activator BAY K8644 (2 μM) and protein kinase A (PKA) activator forskolin (20 μM) revealed enhanced levels of 45Ca at T= 10 min that were 132% and 140% of corresponding controls, respectively (each, P < 0.05). Phorbol ester treatment of the cells resulted in significant increases in the levels of 45Ca between the treated cells and corresponding controls at T=7 and 10 min. Cells treated with 100 nM 25(OH)2D3 revealed 89.8% and 78.4% increases above controls in PKA activity at T =1 min (P < 0.05) and T=3 min, relative to corresponding controls. However, there was no evidence for the activation of PKC by 25(OH)2D3 during the time period studied.

No description available.

Indiana University-Purdue University Indianapolis (IUPUI) / Vitamin D deficiency has been linked to chronic pain and increased opioid use. Realworld data such as electronic medical records and administrative claim data contain large amounts of clinical data and present an opportunity to study the relationship of serum 25- hydroxyvitamin D [25(OH)D] with pain intensity and opioid use. The first study assessed the association between serum 25(OH)D) levels and pain intensity. Compared to patients with normal 25(OH)D levels, those who had insufficient or deficient levels were more likely to experience moderate or severe pain, with multivariable-adjusted odds ratios (95% confidence intervals) of 1.19 (1.05-1.36) and 1.51 (1.28-1.79), respectively. Similar findings were obtained using propensity scores in the matched analyses. In the second study, we investigated the association between serum 25(OH.)D levels and opioid use among opioid-naïve patients. We revealed that those who had insufficient or deficient levels of 25(OH)D were more likely to receive an opioid prescription, with multivariableadjusted odds ratios of 1.10 (1.02-1.17) and 1.18 (1.09-1.28), respectively, compared to patients with normal 25(OH)D levels. Vitamin D deficiency was also associated with a longer duration of opioid use. In the third study, we performed machine learning to identify patient characteristics associated with persistent moderate-to-severe pain (PMSP), explicitly investigating if low serum 25(OH)D levels were a risk factor for heightened pain intensity among obese patients. Low levels of 25(OH)D were consistently identified as a key predictor from a large number of candidate variables in the machine learning models. We detected a significant positive association between serum 25(OH)D levels and PMSP in the logistic regression analysis. Compared to patients with normal levels of 25(OH)D, those who had insufficient or deficient levels of 25(OH)D were more likely to report PMSP, with multivariable-adjusted OR (95% CIs) of 1.15 (1.10-1.21) and 1.28 (1.21-1.35) respectively. We replicated the findings in the first study in a different cohort that showed that low serum 25(OH)D levels might play a role in pain perception. This research contributes to an improved understanding of the role of vitamin D on pain, and opioid use. Individuals who experience pain and need opioid therapy may benefit from optimizing their serum 25(OH)D levels.

No description available.

O diabetes mellitus (DM) é uma doença com prevalência e morbidade elevadas em todo o mundo, sendo que o DM1 é responsável por 5-10% dos casos. A vitamina D, hormônio de ação pleiotrópica, pode melhorar o curso do DM1, embora os mecanismos não estejam completamente elucidados. Dessa forma, ampliar o conhecimento sobre a ação desse hormônio pode auxiliar no prognóstico, bem como na compreensão dos possíveis mecanismos envolvidos na prevenção do DM. Neste trabalho, foram avaliados os efeitos fisiológicos da suplementação de vitamina D (800 UI/dia/sete dias; via oral) em camundongos machos (n=31; linhagem C57BL/6) distribuídos em quatro grupos: Controle + Água (CA; n=9); Controle + Vitamina D (CV; n=9); Diabético + Água (DA; n=6) e Diabético + Vitamina D (DV; n=7). Os camundongos tornados diabéticos (aloxana, 60 mg/Kg, intravenosa), quando comparados aos controles, exibiram redução do peso corporal e concentrações plasmáticas de glicose mais elevadas durante o período experimental de 10 dias (características do estado insulinopênico). Entretanto, a suplementação com vitamina D não alterou essa condição. Camundongos tornados diabéticos, em relação aos controles, exibiram redução do peso corporal (p<0,05) e concentrações plasmáticas de glicose (p<0,001) mais elevadas durante o período experimental. Animais suplementados com vitamina D apresentaram, em relação aos controles, níveis de 25(OH)D mais elevados (CA vs CV, p<0,001; DA vs DV, p<0,001). Níveis séricos maiores de ureia (CA vs DA, p<0,05; CA vs DV, p<0,01; CV vs DA, p<0,05; CV vs DV, p<0,01) e creatinina (CA vs DA, p<0,001; CA vs DV, p<0,001; CV vs DA, p<0,001; CV vs DV, p<0,001), espessamento da cápsula de Bowman, hipertrofia glomerular e destruição de hepatócitos foram observados em camundongos diabéticos em relação aos controles. Entretanto, a suplementação com vitamina D não alterou estas condições. O grupo DA apresentou menor nível sérico de albumina em relação aos grupos CA (p<0,05) e CV (p<0,05); níveis inferiores de hemoglobina (p<0,05) e hematócrito (p<0,05) em relação ao grupo DV; e menor leucometria (p<0,05) e mononucleares sanguíneos (p<0,05) em relação ao grupo CA. Os resultados sugerem que a vitamina D possa influenciar a resposta imunológica em animais diabéticos, modulando hematócrito, hemoglobina, bem como os níveis séricos de albumina / Diabetes mellitus (DM) is a disease with high prevalence and morbidity worldwide, and the DM1 is responsible for 5-10% of cases. The vitamin D hormone pleiotropic action, can improve the course of T1DM, although the mechanisms are not fully elucidated. Thus, better understanding the action of this hormone can aid in prognosis as well as in understanding the possible mechanisms involved in the prevention of diabetes. We evaluated the physiological effects of vitamin D (800 IU/day/seven days, v.o.) in male mice (n=31, C57BL/6 strain) divided into four groups: Control + Water (CW, n=9); Control Vitamin D + (CV n=9); Diabetic + Water (DW, n=6) Diabetic + Vitamin D (VD, n=7). The mice induced-diabetes by alloxan (60 mg/kg, i.v.), when compared to controls, exhibited reduced body weight and plasma glucose concentrations were higher during the experimental period of 10 days (features insulinopenic state). However, vitamin D supplementation did not alter this condition. Diabetic mice, compared to controls, exhibited reduced body weight (p<0,05) and plasma glucose concentrations (p <0.001) higher during the trial period. Animals supplemented with vitamin D showed higher levels of 25 (OH) D than controls (CW vs CV, p <0,001; DW vs DV, p<0,001). Higher serum urea (CW vs. DW, p <0,05; CW vs DV, p <0,01; CV vs DA, p <0,05; CV vs DV, p <0,01) and creatinine (CW vs. DW, p <0,001; CW vs DV, p <0,001; CV vs DW, p <0,001; CV vs DW, p <0,001), thickening of Bowman\'s capsule, glomerular hypertrophy and destruction of hepatocytes were observed in diabetic mice compared to controls. However, vitamin D supplementation did not alter these conditions. The DW group showed lower serum albumin compared to CW (p<0,05) and CV (p<0,05) groups; lower hemoglobin (p<0,05) and hematocrit (p <0,05) compared to the DV group; and lower leukocyte counts compared to CW (p <0,05) and mononuclear blood (p <0,05) compared to the CW group. The results suggest that Vitamin D may influence the immune response in diabetic animals, modulating hematocrit, hemoglobin and serum albumin

O diabetes mellitus (DM) é uma doença com prevalência e morbidade elevadas em todo o mundo, sendo que o DM1 é responsável por 5-10% dos casos. A vitamina D, hormônio de ação pleiotrópica, pode melhorar o curso do DM1, embora os mecanismos não estejam completamente elucidados. Dessa forma, ampliar o conhecimento sobre a ação desse hormônio pode auxiliar no prognóstico, bem como na compreensão dos possíveis mecanismos envolvidos na prevenção do DM. Neste trabalho, foram avaliados os efeitos fisiológicos da suplementação de vitamina D (800 UI/dia/sete dias; via oral) em camundongos machos (n=31; linhagem C57BL/6) distribuídos em quatro grupos: Controle + Água (CA; n=9); Controle + Vitamina D (CV; n=9); Diabético + Água (DA; n=6) e Diabético + Vitamina D (DV; n=7). Os camundongos tornados diabéticos (aloxana, 60 mg/Kg, intravenosa), quando comparados aos controles, exibiram redução do peso corporal e concentrações plasmáticas de glicose mais elevadas durante o período experimental de 10 dias (características do estado insulinopênico). Entretanto, a suplementação com vitamina D não alterou essa condição. Camundongos tornados diabéticos, em relação aos controles, exibiram redução do peso corporal (p<0,05) e concentrações plasmáticas de glicose (p<0,001) mais elevadas durante o período experimental. Animais suplementados com vitamina D apresentaram, em relação aos controles, níveis de 25(OH)D mais elevados (CA vs CV, p<0,001; DA vs DV, p<0,001). Níveis séricos maiores de ureia (CA vs DA, p<0,05; CA vs DV, p<0,01; CV vs DA, p<0,05; CV vs DV, p<0,01) e creatinina (CA vs DA, p<0,001; CA vs DV, p<0,001; CV vs DA, p<0,001; CV vs DV, p<0,001), espessamento da cápsula de Bowman, hipertrofia glomerular e destruição de hepatócitos foram observados em camundongos diabéticos em relação aos controles. Entretanto, a suplementação com vitamina D não alterou estas condições. O grupo DA apresentou menor nível sérico de albumina em relação aos grupos CA (p<0,05) e CV (p<0,05); níveis inferiores de hemoglobina (p<0,05) e hematócrito (p<0,05) em relação ao grupo DV; e menor leucometria (p<0,05) e mononucleares sanguíneos (p<0,05) em relação ao grupo CA. Os resultados sugerem que a vitamina D possa influenciar a resposta imunológica em animais diabéticos, modulando hematócrito, hemoglobina, bem como os níveis séricos de albumina / Diabetes mellitus (DM) is a disease with high prevalence and morbidity worldwide, and the DM1 is responsible for 5-10% of cases. The vitamin D hormone pleiotropic action, can improve the course of T1DM, although the mechanisms are not fully elucidated. Thus, better understanding the action of this hormone can aid in prognosis as well as in understanding the possible mechanisms involved in the prevention of diabetes. We evaluated the physiological effects of vitamin D (800 IU/day/seven days, v.o.) in male mice (n=31, C57BL/6 strain) divided into four groups: Control + Water (CW, n=9); Control Vitamin D + (CV n=9); Diabetic + Water (DW, n=6) Diabetic + Vitamin D (VD, n=7). The mice induced-diabetes by alloxan (60 mg/kg, i.v.), when compared to controls, exhibited reduced body weight and plasma glucose concentrations were higher during the experimental period of 10 days (features insulinopenic state). However, vitamin D supplementation did not alter this condition. Diabetic mice, compared to controls, exhibited reduced body weight (p<0,05) and plasma glucose concentrations (p <0.001) higher during the trial period. Animals supplemented with vitamin D showed higher levels of 25 (OH) D than controls (CW vs CV, p <0,001; DW vs DV, p<0,001). Higher serum urea (CW vs. DW, p <0,05; CW vs DV, p <0,01; CV vs DA, p <0,05; CV vs DV, p <0,01) and creatinine (CW vs. DW, p <0,001; CW vs DV, p <0,001; CV vs DW, p <0,001; CV vs DW, p <0,001), thickening of Bowman\'s capsule, glomerular hypertrophy and destruction of hepatocytes were observed in diabetic mice compared to controls. However, vitamin D supplementation did not alter these conditions. The DW group showed lower serum albumin compared to CW (p<0,05) and CV (p<0,05) groups; lower hemoglobin (p<0,05) and hematocrit (p <0,05) compared to the DV group; and lower leukocyte counts compared to CW (p <0,05) and mononuclear blood (p <0,05) compared to the CW group. The results suggest that Vitamin D may influence the immune response in diabetic animals, modulating hematocrit, hemoglobin and serum albumin